Share Price and Basic Stock Data
Last Updated: January 17, 2026, 7:09 am
| PEG Ratio | 0.86 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Indraprastha Medical Corporation Ltd operates within the hospitals and medical services industry, showcasing a robust growth trajectory in its revenue. The company reported sales of ₹1,099 Cr for the fiscal year ending March 2023, which rose to ₹1,245 Cr in March 2024 and is projected to reach ₹1,356 Cr in March 2025. This consistent upward trend reflects a commendable compound annual growth rate (CAGR) in a sector that typically averages lower growth rates. The company’s quarterly sales also indicate resilience, with the latest reported figure for September 2023 standing at ₹317 Cr, an increase from ₹284 Cr in September 2022. This growth is indicative of the company’s expanding operational footprint and an increasing demand for healthcare services. The operating profit margin (OPM) also improved from 14% in March 2022 to 18% in March 2025, highlighting enhanced operational efficiency as the company scales its services.
Profitability and Efficiency Metrics
Indraprastha Medical Corporation Ltd has demonstrated strong profitability metrics, recording a net profit of ₹175 Cr for the trailing twelve months, with a net profit margin of 11.86% as of March 2025. This margin has improved from 6.60% in March 2022, showcasing the company’s ability to enhance its profitability amidst rising operational costs. The return on equity (ROE) stood at an impressive 30%, significantly higher than typical sector averages of around 15-20%, indicating effective utilization of shareholders’ funds. Furthermore, the return on capital employed (ROCE) rose to 39.1%, reflecting efficient management of capital in generating profits. The interest coverage ratio is exceptionally high at 42.57x, suggesting that the company can comfortably meet its interest obligations, which is a significant strength in a capital-intensive industry like healthcare.
Balance Sheet Strength and Financial Ratios
The balance sheet of Indraprastha Medical Corporation Ltd reveals a solid financial position, with total assets amounting to ₹852 Cr as of March 2025, up from ₹723 Cr in March 2024. The company’s reserves have also shown a healthy increase, reaching ₹567 Cr by September 2025, indicating a strong capacity for reinvestment and growth. With borrowings of just ₹31 Cr, the company maintains a low leverage ratio, which is advantageous in times of economic uncertainty. The current ratio of 2.41x and quick ratio of 2.37x further affirm the company’s liquidity position, exceeding the typical sector benchmarks. However, the price-to-book value ratio stood at 5.93x, indicating that the stock may be overvalued compared to its net assets, which could be a concern for value-oriented investors.
Shareholding Pattern and Investor Confidence
Indraprastha Medical Corporation Ltd exhibits a stable shareholding pattern, with promoters holding 51% of the equity, ensuring strong control and aligned interests with shareholders. Institutional investors are gradually increasing their stake, with foreign institutional investors (FIIs) at 2.41% and domestic institutional investors (DIIs) at 3.51%, suggesting growing confidence in the company’s prospects. The total number of shareholders increased to 70,914 by September 2025, reflecting rising retail interest. However, the public holding decreased to 43.08%, indicating a consolidation of ownership among institutional and promoter groups. This trend may enhance governance but could also limit liquidity in the stock. The company’s consistent dividend payout, which stood at ₹4.50 per share in March 2025, further signals a commitment to returning value to shareholders, bolstering investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, Indraprastha Medical Corporation Ltd is well-positioned to capitalize on the growing demand for healthcare services, bolstered by its strong financial metrics and operational efficiency. However, risks such as potential regulatory changes in the healthcare sector and rising operational costs could impact profitability. Additionally, the company’s high price-to-book value ratio may deter some investors concerned about valuation. Despite these risks, the company’s strong balance sheet, high ROE, and consistent dividend policy provide a solid foundation for growth. If the company successfully navigates these challenges while maintaining its growth trajectory, it could enhance shareholder value significantly in the long term. Investors should monitor the company’s ability to adapt to market dynamics and its efforts to sustain profitability amidst external pressures.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.6 Cr. | 136 | 187/120 | 9.31 | 117 | 2.57 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 23.3 Cr. | 22.2 | 33.8/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.8 Cr. | 10.5 | 20.5/7.08 | 121 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 108 Cr. | 57.7 | 98.7/55.2 | 23.9 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.4 Cr. | 3.60 | 6.94/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,030.64 Cr | 690.98 | 90.24 | 93.18 | 0.34% | 15.48% | 14.81% | 9.04 |
All Competitor Stocks of Indraprastha Medical Corporation Ltd
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 284 | 277 | 274 | 307 | 317 | 306 | 315 | 348 | 350 | 325 | 334 | 365 | 381 |
| Expenses | 241 | 240 | 241 | 259 | 267 | 259 | 266 | 281 | 286 | 273 | 272 | 292 | 310 |
| Operating Profit | 44 | 37 | 33 | 47 | 50 | 47 | 48 | 67 | 64 | 52 | 61 | 73 | 71 |
| OPM % | 15% | 13% | 12% | 15% | 16% | 15% | 15% | 19% | 18% | 16% | 18% | 20% | 19% |
| Other Income | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 5 | 6 | 5 | 6 | 7 | 7 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 |
| Depreciation | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 10 | 11 |
| Profit before tax | 34 | 29 | 27 | 40 | 44 | 41 | 42 | 60 | 57 | 45 | 55 | 68 | 66 |
| Tax % | 26% | 29% | 27% | 24% | 25% | 28% | 25% | 25% | 26% | 26% | 26% | 25% | 25% |
| Net Profit | 25 | 21 | 20 | 30 | 33 | 29 | 31 | 45 | 42 | 33 | 41 | 51 | 49 |
| EPS in Rs | 2.74 | 2.28 | 2.16 | 3.33 | 3.58 | 3.21 | 3.40 | 4.88 | 4.63 | 3.58 | 4.47 | 5.61 | 5.40 |
Last Updated: January 1, 2026, 7:16 am
Below is a detailed analysis of the quarterly data for Indraprastha Medical Corporation Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 381.00 Cr.. The value appears strong and on an upward trend. It has increased from 365.00 Cr. (Jun 2025) to 381.00 Cr., marking an increase of 16.00 Cr..
- For Expenses, as of Sep 2025, the value is 310.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 292.00 Cr. (Jun 2025) to 310.00 Cr., marking an increase of 18.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 71.00 Cr.. The value appears to be declining and may need further review. It has decreased from 73.00 Cr. (Jun 2025) to 71.00 Cr., marking a decrease of 2.00 Cr..
- For OPM %, as of Sep 2025, the value is 19.00%. The value appears to be declining and may need further review. It has decreased from 20.00% (Jun 2025) to 19.00%, marking a decrease of 1.00%.
- For Other Income, as of Sep 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 7.00 Cr..
- For Interest, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 2.00 Cr..
- For Depreciation, as of Sep 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Jun 2025) to 11.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 66.00 Cr.. The value appears to be declining and may need further review. It has decreased from 68.00 Cr. (Jun 2025) to 66.00 Cr., marking a decrease of 2.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 25.00%.
- For Net Profit, as of Sep 2025, the value is 49.00 Cr.. The value appears to be declining and may need further review. It has decreased from 51.00 Cr. (Jun 2025) to 49.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 5.40. The value appears to be declining and may need further review. It has decreased from 5.61 (Jun 2025) to 5.40, marking a decrease of 0.21.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:11 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 678 | 714 | 755 | 766 | 753 | 788 | 831 | 613 | 888 | 1,099 | 1,245 | 1,356 | 1,405 |
| Expenses | 587 | 630 | 675 | 686 | 678 | 706 | 743 | 572 | 768 | 947 | 1,050 | 1,112 | 1,147 |
| Operating Profit | 91 | 85 | 80 | 79 | 74 | 82 | 87 | 41 | 120 | 152 | 195 | 245 | 258 |
| OPM % | 13% | 12% | 11% | 10% | 10% | 10% | 11% | 7% | 14% | 14% | 16% | 18% | 18% |
| Other Income | 1 | 1 | 1 | -0 | -1 | -1 | -0 | -0 | -3 | 9 | 16 | 22 | 26 |
| Interest | 10 | 8 | 7 | 8 | 9 | 7 | 6 | 3 | 3 | 4 | 4 | 6 | 6 |
| Depreciation | 28 | 28 | 35 | 31 | 31 | 30 | 33 | 33 | 35 | 39 | 40 | 44 | 43 |
| Profit before tax | 54 | 50 | 39 | 41 | 34 | 45 | 48 | 4 | 79 | 117 | 166 | 216 | 234 |
| Tax % | 35% | 34% | 37% | 36% | 38% | 36% | 9% | 46% | 26% | 26% | 25% | 26% | |
| Net Profit | 35 | 32 | 24 | 26 | 21 | 28 | 44 | 2 | 59 | 86 | 124 | 161 | 175 |
| EPS in Rs | 3.87 | 3.54 | 2.66 | 2.86 | 2.30 | 3.10 | 4.76 | 0.25 | 6.39 | 9.40 | 13.52 | 17.56 | 19.06 |
| Dividend Payout % | 47% | 51% | 68% | 63% | 65% | 52% | 0% | 0% | 39% | 32% | 33% | 26% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -8.57% | -25.00% | 8.33% | -19.23% | 33.33% | 57.14% | -95.45% | 2850.00% | 45.76% | 44.19% | 29.84% |
| Change in YoY Net Profit Growth (%) | 0.00% | -16.43% | 33.33% | -27.56% | 52.56% | 23.81% | -152.60% | 2945.45% | -2804.24% | -1.58% | -14.35% |
Indraprastha Medical Corporation Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 10% |
| 3 Years: | 15% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 29% |
| 3 Years: | 37% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 58% |
| 3 Years: | 89% |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 23% |
| 3 Years: | 28% |
| Last Year: | 30% |
Last Updated: September 5, 2025, 7:30 am
Balance Sheet
Last Updated: December 10, 2025, 2:51 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 | 92 |
| Reserves | 95 | 103 | 132 | 139 | 141 | 152 | 176 | 181 | 234 | 288 | 386 | 505 | 567 |
| Borrowings | 63 | 50 | 52 | 67 | 66 | 21 | 4 | 3 | 5 | 2 | 34 | 33 | 31 |
| Other Liabilities | 199 | 196 | 185 | 160 | 134 | 157 | 177 | 157 | 131 | 173 | 212 | 222 | 264 |
| Total Liabilities | 449 | 442 | 460 | 458 | 432 | 422 | 449 | 432 | 462 | 555 | 723 | 852 | 954 |
| Fixed Assets | 293 | 286 | 301 | 296 | 294 | 280 | 303 | 283 | 277 | 275 | 347 | 328 | 351 |
| CWIP | 2 | 3 | 3 | 0 | 0 | 1 | 0 | 3 | 0 | 3 | 0 | 33 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39 |
| Other Assets | 154 | 153 | 157 | 163 | 138 | 141 | 146 | 145 | 185 | 278 | 376 | 491 | 563 |
| Total Assets | 449 | 442 | 460 | 458 | 432 | 422 | 449 | 432 | 462 | 555 | 723 | 852 | 954 |
Below is a detailed analysis of the balance sheet data for Indraprastha Medical Corporation Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 92.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 92.00 Cr..
- For Reserves, as of Sep 2025, the value is 567.00 Cr.. The value appears strong and on an upward trend. It has increased from 505.00 Cr. (Mar 2025) to 567.00 Cr., marking an increase of 62.00 Cr..
- For Borrowings, as of Sep 2025, the value is 31.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 33.00 Cr. (Mar 2025) to 31.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 264.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 222.00 Cr. (Mar 2025) to 264.00 Cr., marking an increase of 42.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 954.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 852.00 Cr. (Mar 2025) to 954.00 Cr., marking an increase of 102.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 351.00 Cr.. The value appears strong and on an upward trend. It has increased from 328.00 Cr. (Mar 2025) to 351.00 Cr., marking an increase of 23.00 Cr..
- For CWIP, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 31.00 Cr..
- For Investments, as of Sep 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 39.00 Cr..
- For Other Assets, as of Sep 2025, the value is 563.00 Cr.. The value appears strong and on an upward trend. It has increased from 491.00 Cr. (Mar 2025) to 563.00 Cr., marking an increase of 72.00 Cr..
- For Total Assets, as of Sep 2025, the value is 954.00 Cr.. The value appears strong and on an upward trend. It has increased from 852.00 Cr. (Mar 2025) to 954.00 Cr., marking an increase of 102.00 Cr..
Notably, the Reserves (567.00 Cr.) exceed the Borrowings (31.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 28.00 | 35.00 | 28.00 | 12.00 | 8.00 | 61.00 | 83.00 | 38.00 | 115.00 | 150.00 | 161.00 | 212.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 40 | 41 | 47 | 41 | 35 | 35 | 40 | 18 | 23 | 17 | 20 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 35 | 40 | 41 | 47 | 41 | 35 | 35 | 40 | 18 | 23 | 17 | 20 |
| Working Capital Days | -27 | -35 | -22 | -17 | -7 | -5 | -10 | -1 | -2 | -12 | -24 | -19 |
| ROCE % | 26% | 23% | 18% | 17% | 15% | 19% | 21% | 3% | 29% | 34% | 38% | 39% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 721,778 | 0.14 | 43.77 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 17.56 | 13.52 | 9.40 | 6.39 | 0.25 |
| Diluted EPS (Rs.) | 17.56 | 13.52 | 9.40 | 6.39 | 0.25 |
| Cash EPS (Rs.) | 22.40 | 17.89 | 13.68 | 10.21 | 3.89 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 65.09 | 52.12 | 41.39 | 35.50 | 29.75 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 65.09 | 52.12 | 41.39 | 35.50 | 29.75 |
| Dividend / Share (Rs.) | 4.50 | 4.50 | 3.00 | 2.50 | 0.00 |
| Revenue From Operations / Share (Rs.) | 147.96 | 135.78 | 119.85 | 96.89 | 66.91 |
| PBDIT / Share (Rs.) | 29.12 | 22.93 | 17.53 | 12.81 | 4.47 |
| PBIT / Share (Rs.) | 24.28 | 18.56 | 13.25 | 9.00 | 0.83 |
| PBT / Share (Rs.) | 23.60 | 18.12 | 12.78 | 8.63 | 0.46 |
| Net Profit / Share (Rs.) | 17.56 | 13.52 | 9.40 | 6.39 | 0.25 |
| PBDIT Margin (%) | 19.67 | 16.89 | 14.62 | 13.22 | 6.67 |
| PBIT Margin (%) | 16.41 | 13.67 | 11.05 | 9.28 | 1.24 |
| PBT Margin (%) | 15.94 | 13.34 | 10.66 | 8.90 | 0.69 |
| Net Profit Margin (%) | 11.86 | 9.95 | 7.84 | 6.60 | 0.37 |
| Return on Networth / Equity (%) | 26.98 | 25.94 | 22.70 | 18.01 | 0.85 |
| Return on Capital Employeed (%) | 33.07 | 30.50 | 28.54 | 22.40 | 2.41 |
| Return On Assets (%) | 18.90 | 17.13 | 15.51 | 12.69 | 0.53 |
| Asset Turnover Ratio (%) | 1.72 | 1.95 | 2.16 | 1.99 | 1.39 |
| Current Ratio (X) | 2.41 | 1.86 | 1.72 | 1.68 | 1.22 |
| Quick Ratio (X) | 2.37 | 1.82 | 1.66 | 1.58 | 1.14 |
| Inventory Turnover Ratio (X) | 186.83 | 0.00 | 21.00 | 18.55 | 10.95 |
| Dividend Payout Ratio (NP) (%) | 25.62 | 22.18 | 26.60 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 20.09 | 16.76 | 18.27 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 74.38 | 77.82 | 73.40 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 79.91 | 83.24 | 81.73 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 42.57 | 51.79 | 37.55 | 34.43 | 12.27 |
| Interest Coverage Ratio (Post Tax) (X) | 26.68 | 31.53 | 21.13 | 18.19 | 1.70 |
| Enterprise Value (Cr.) | 3217.17 | 1350.00 | 583.80 | 467.36 | 465.22 |
| EV / Net Operating Revenue (X) | 2.37 | 1.08 | 0.53 | 0.52 | 0.75 |
| EV / EBITDA (X) | 12.05 | 6.42 | 3.63 | 3.98 | 11.36 |
| MarketCap / Net Operating Revenue (X) | 2.61 | 1.26 | 0.64 | 0.60 | 0.80 |
| Retention Ratios (%) | 74.37 | 77.81 | 73.39 | 0.00 | 0.00 |
| Price / BV (X) | 5.93 | 3.30 | 1.88 | 1.65 | 1.81 |
| Price / Net Operating Revenue (X) | 2.61 | 1.26 | 0.64 | 0.60 | 0.80 |
| EarningsYield | 0.04 | 0.07 | 0.12 | 0.10 | 0.00 |
After reviewing the key financial ratios for Indraprastha Medical Corporation Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 17.56. This value is within the healthy range. It has increased from 13.52 (Mar 24) to 17.56, marking an increase of 4.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 17.56. This value is within the healthy range. It has increased from 13.52 (Mar 24) to 17.56, marking an increase of 4.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 22.40. This value is within the healthy range. It has increased from 17.89 (Mar 24) to 22.40, marking an increase of 4.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.09. It has increased from 52.12 (Mar 24) to 65.09, marking an increase of 12.97.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.09. It has increased from 52.12 (Mar 24) to 65.09, marking an increase of 12.97.
- For Dividend / Share (Rs.), as of Mar 25, the value is 4.50. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 4.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 147.96. It has increased from 135.78 (Mar 24) to 147.96, marking an increase of 12.18.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 29.12. This value is within the healthy range. It has increased from 22.93 (Mar 24) to 29.12, marking an increase of 6.19.
- For PBIT / Share (Rs.), as of Mar 25, the value is 24.28. This value is within the healthy range. It has increased from 18.56 (Mar 24) to 24.28, marking an increase of 5.72.
- For PBT / Share (Rs.), as of Mar 25, the value is 23.60. This value is within the healthy range. It has increased from 18.12 (Mar 24) to 23.60, marking an increase of 5.48.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 17.56. This value is within the healthy range. It has increased from 13.52 (Mar 24) to 17.56, marking an increase of 4.04.
- For PBDIT Margin (%), as of Mar 25, the value is 19.67. This value is within the healthy range. It has increased from 16.89 (Mar 24) to 19.67, marking an increase of 2.78.
- For PBIT Margin (%), as of Mar 25, the value is 16.41. This value is within the healthy range. It has increased from 13.67 (Mar 24) to 16.41, marking an increase of 2.74.
- For PBT Margin (%), as of Mar 25, the value is 15.94. This value is within the healthy range. It has increased from 13.34 (Mar 24) to 15.94, marking an increase of 2.60.
- For Net Profit Margin (%), as of Mar 25, the value is 11.86. This value exceeds the healthy maximum of 10. It has increased from 9.95 (Mar 24) to 11.86, marking an increase of 1.91.
- For Return on Networth / Equity (%), as of Mar 25, the value is 26.98. This value is within the healthy range. It has increased from 25.94 (Mar 24) to 26.98, marking an increase of 1.04.
- For Return on Capital Employeed (%), as of Mar 25, the value is 33.07. This value is within the healthy range. It has increased from 30.50 (Mar 24) to 33.07, marking an increase of 2.57.
- For Return On Assets (%), as of Mar 25, the value is 18.90. This value is within the healthy range. It has increased from 17.13 (Mar 24) to 18.90, marking an increase of 1.77.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.72. It has decreased from 1.95 (Mar 24) to 1.72, marking a decrease of 0.23.
- For Current Ratio (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has increased from 1.86 (Mar 24) to 2.41, marking an increase of 0.55.
- For Quick Ratio (X), as of Mar 25, the value is 2.37. This value exceeds the healthy maximum of 2. It has increased from 1.82 (Mar 24) to 2.37, marking an increase of 0.55.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 186.83. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 186.83, marking an increase of 186.83.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 25.62. This value is within the healthy range. It has increased from 22.18 (Mar 24) to 25.62, marking an increase of 3.44.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.09. This value is within the healthy range. It has increased from 16.76 (Mar 24) to 20.09, marking an increase of 3.33.
- For Earning Retention Ratio (%), as of Mar 25, the value is 74.38. This value exceeds the healthy maximum of 70. It has decreased from 77.82 (Mar 24) to 74.38, marking a decrease of 3.44.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.91. This value exceeds the healthy maximum of 70. It has decreased from 83.24 (Mar 24) to 79.91, marking a decrease of 3.33.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 42.57. This value is within the healthy range. It has decreased from 51.79 (Mar 24) to 42.57, marking a decrease of 9.22.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 26.68. This value is within the healthy range. It has decreased from 31.53 (Mar 24) to 26.68, marking a decrease of 4.85.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,217.17. It has increased from 1,350.00 (Mar 24) to 3,217.17, marking an increase of 1,867.17.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.37. This value is within the healthy range. It has increased from 1.08 (Mar 24) to 2.37, marking an increase of 1.29.
- For EV / EBITDA (X), as of Mar 25, the value is 12.05. This value is within the healthy range. It has increased from 6.42 (Mar 24) to 12.05, marking an increase of 5.63.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 2.61, marking an increase of 1.35.
- For Retention Ratios (%), as of Mar 25, the value is 74.37. This value exceeds the healthy maximum of 70. It has decreased from 77.81 (Mar 24) to 74.37, marking a decrease of 3.44.
- For Price / BV (X), as of Mar 25, the value is 5.93. This value exceeds the healthy maximum of 3. It has increased from 3.30 (Mar 24) to 5.93, marking an increase of 2.63.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 2.61, marking an increase of 1.35.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to 0.04, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Indraprastha Medical Corporation Ltd:
- Net Profit Margin: 11.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 33.07% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 26.98% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 26.68
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.37
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 21.1 (Industry average Stock P/E: 90.24)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.86%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Sarita Vihar, New Delhi Delhi 110076 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Prathap C Reddy | Vice Chairman |
| Mr. Shivakumar Pattabhiraman | Managing Director |
| Mr. Sudhir Jalan | Director |
| Prof. (Dr) Mahesh Verma | Director |
| Mr. Salil Singhal | Director |
| Dr.(Ms.) Suneeta Reddy | Director |
| Mr. Vinayak Chatterjee | Director |
| Ms. Vineeta Rai | Director |
| Mr. Sandip Somany | Director |
| Mr. Tejpreet Singh Chopra | Director |
| Ms. Madhumita Ganguli | Director |
| Dr.(Ms.) Sangita Reddy | Director |
FAQ
What is the intrinsic value of Indraprastha Medical Corporation Ltd?
Indraprastha Medical Corporation Ltd's intrinsic value (as of 17 January 2026) is ₹457.49 which is 13.80% higher the current market price of ₹402.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,690 Cr. market cap, FY2025-2026 high/low of ₹641/307, reserves of ₹567 Cr, and liabilities of ₹954 Cr.
What is the Market Cap of Indraprastha Medical Corporation Ltd?
The Market Cap of Indraprastha Medical Corporation Ltd is 3,690 Cr..
What is the current Stock Price of Indraprastha Medical Corporation Ltd as on 17 January 2026?
The current stock price of Indraprastha Medical Corporation Ltd as on 17 January 2026 is ₹402.
What is the High / Low of Indraprastha Medical Corporation Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Indraprastha Medical Corporation Ltd stocks is ₹641/307.
What is the Stock P/E of Indraprastha Medical Corporation Ltd?
The Stock P/E of Indraprastha Medical Corporation Ltd is 21.1.
What is the Book Value of Indraprastha Medical Corporation Ltd?
The Book Value of Indraprastha Medical Corporation Ltd is 71.8.
What is the Dividend Yield of Indraprastha Medical Corporation Ltd?
The Dividend Yield of Indraprastha Medical Corporation Ltd is 1.12 %.
What is the ROCE of Indraprastha Medical Corporation Ltd?
The ROCE of Indraprastha Medical Corporation Ltd is 39.1 %.
What is the ROE of Indraprastha Medical Corporation Ltd?
The ROE of Indraprastha Medical Corporation Ltd is 30.0 %.
What is the Face Value of Indraprastha Medical Corporation Ltd?
The Face Value of Indraprastha Medical Corporation Ltd is 10.0.